LIXT LIXTE BIOTECHNOLOGY HOLDING...

Nasdaq lixte.com


$ 4.35 $ 0.04 (0.91 %)    

Thursday, 20-Nov-2025 15:44:10 EST
QQQ $ 585.81 $ -25.86 (-4.23 %)
DIA $ 458.41 $ -8.24 (-1.77 %)
SPY $ 652.99 $ -19.91 (-2.96 %)
TLT $ 89.28 $ 0.29 (0.32 %)
GLD $ 374.72 $ -0.48 (-0.13 %)
$ 4.33
$ 4.40
$ 4.34 x 100
$ 4.43 x 100
$ 4.40 - $ 4.44
$ 0.64 - $ 6.26
70,051
na
24.7M
$ 0.76
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-24-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-19-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-29-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-10-2022 06-30-2022 10-Q
15 05-11-2022 03-31-2022 10-Q
16 03-21-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-10-2021 06-30-2021 10-Q
19 05-12-2021 03-31-2021 10-Q
20 03-26-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-25-2020 12-31-2019 10-K
25 11-08-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 03-25-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 04-27-2018 03-31-2018 10-Q
32 03-23-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-04-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-29-2017 12-31-2016 10-K
37 11-04-2016 09-30-2016 10-Q
38 08-10-2016 06-30-2016 10-Q
39 05-06-2016 03-31-2016 10-Q
40 03-28-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lixte-biotech-hldgs-q2-eps-029-up-from-045-yoy

Lixte Biotech Hldgs (NASDAQ:LIXT) reported quarterly losses of $(0.29) per share. This is a 35.56 percent increase over losses ...

 lixte-biotechnologys-lb100-highlighted-in-nature-study-showing-pp2a-inhibition-enhances-immunotherapy-response-in-ovarian-and-colorectal-cancers

Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE's Proprietary Compound LB100PASADENA, C...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION